Paul D. Dobson

4.8k total citations
24 papers, 1.9k citations indexed

About

Paul D. Dobson is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Paul D. Dobson has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Pharmacology. Recurrent topics in Paul D. Dobson's work include Microbial Metabolic Engineering and Bioproduction (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Paul D. Dobson is often cited by papers focused on Microbial Metabolic Engineering and Bioproduction (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Paul D. Dobson collaborates with scholars based in United Kingdom, Japan and United States. Paul D. Dobson's co-authors include Douglas B. Kell, Andrew J. Doig, Stephen G. Oliver, Yogendra Patel, Elizabeth Bilsland, Neil Swainston, Karin Lanthaler, Warwick B. Dunn, Glenn Reeves and M Loewenthal and has published in prestigious journals such as Bioinformatics, PLoS ONE and Journal of Molecular Biology.

In The Last Decade

Paul D. Dobson

24 papers receiving 1.9k citations

Peers

Countries citing papers authored by Paul D. Dobson

Since Specialization

Citations

This map shows the geographic impact of Paul D. Dobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul D. Dobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul D. Dobson more than expected).

Fields of papers citing papers by Paul D. Dobson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul D. Dobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul D. Dobson. The network helps show where Paul D. Dobson may publish in the future.

Co-authorship network of co-authors of Paul D. Dobson

This figure shows the co-authorship network connecting the top 25 collaborators of Paul D. Dobson. A scholar is included among the top collaborators of Paul D. Dobson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul D. Dobson. Paul D. Dobson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	biochem4j: Integrated and extensible biochemical knowledge through graph databases 2017 ·PLoS ONE ·Neil Swainston, Riza Batista-Navarro, Pablo Carbonell, Paul D. Dobson, Mark S. Dunstan, Adrian J. Jervis, María Vinaixa, Alan Williams, Sophia Ananiadou, Jean‐Loup Faulon, Pedro Mendes, Douglas B. Kell, Nigel S. Scrutton, Rainer Breitling	26
2	The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so 2012 ·Drug Discovery Today ·Douglas B. Kell, Paul D. Dobson, Elizabeth Bilsland, Stephen G. Oliver	102
3	Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast 2011 ·BMC Biology ·Karin Lanthaler, Elizabeth Bilsland, Paul D. Dobson, (unknown), Pınar Pir, Douglas B. Kell, Stephen G. Oliver	53
4	Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only 2011 ·Drug Discovery Today ·Douglas B. Kell, Paul D. Dobson, Stephen G. Oliver	139
5	Further developments towards a genome-scale metabolic model of yeast 2010 ·BMC Systems Biology ·Paul D. Dobson, Kieran Smallbone, Daniel Jameson, Evangelos Simeonidis, Karin Lanthaler, Pınar Pir, Chuan Lü, Neil Swainston, Warwick B. Dunn, Paul G. Fisher, Duncan Hull, Marie Brown, (unknown), Natalie Stanford, Douglas B. Kell, Ross D. King, Stephen G. Oliver, Robert Stevens, Pedro Mendes	82
6	Text mining meets workflow: linking U-Compare with Taverna 2010 ·Bioinformatics ·Yoshinobu Kano, Paul D. Dobson, Mio Nakanishi, Jun’ichi Tsujii, Sophia Ananiadou	14
7	Mining metabolites: extracting the yeast metabolome from the literature 2010 ·Metabolomics ·Chikashi Nobata, Paul D. Dobson, Syed Amir Iqbal, Pedro Mendes, Jun’ichi Tsujii, Douglas B. Kell, Sophia Ananiadou	35
8	Integration of metabolic databases for the reconstruction of genome-scale metabolic networks 2010 ·BMC Systems Biology ·(unknown), Yoshimasa Tsuruoka, Paul D. Dobson, (unknown), Neil Swainston, Gino Baart, Jean‐Marc Schwartz	70
9	Implications of the Dominant Role of Transporters in Drug Uptake by Cells (Supplementary Material) 2009 ·Current Topics in Medicinal Chemistry ·Paul D. Dobson, Karin Lanthaler, Stephen G. Oliver, Douglas B. Kell	68
10	Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics 2009 ·The Analyst ·Martin Brown, Warwick B. Dunn, Paul D. Dobson, Y. Patel, Catherine Winder, Sue Francis‐McIntyre, Paul Begley, Kathleen Carroll, David Broadhurst, Andy Tseng, Neil Swainston, ‪Irena Spasić, Royston Goodacre, Douglas B. Kell	195
11	The cellular uptake of pharmaceutical drugs is mainly carrier-mediated and is thus an issue not so much of biophysics but of systems biology 2009 ·Research Explorer (The University of Manchester) ·Douglas B. Kell, Paul D. Dobson	19
12	‘Metabolite-likeness’ as a criterion in the design and selection of pharmaceutical drug libraries 2008 ·Drug Discovery Today ·Paul D. Dobson, Yogendra Patel, Douglas B. Kell	105
13	Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? 2008 ·Nature Reviews Drug Discovery ·Paul D. Dobson, Douglas B. Kell	350
14	National comparative audit of the use of platelet transfusions in the UK 2007 ·Transfusion Clinique et Biologique ·Hamna J. Qureshi, D. Lowe, Paul D. Dobson, John Grant‐Casey, (unknown), David Dalton, Keith G. Hickling, (unknown), Carol A. Howell, Michael Murphy	47
15	Predicting Enzyme Class From Protein Structure Without Alignments 2004 ·Journal of Molecular Biology ·Paul D. Dobson, Andrew J. Doig	122
16	Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation 2004 ·Internal Medicine Journal ·Glenn Reeves, (unknown), (unknown), Paul D. Dobson, M Loewenthal	84
17	Prediction of Protein Function in the Absence of Significant Sequence Similarity 2004 ·Current Medicinal Chemistry ·Paul D. Dobson, Yu‐Dong Cai, Benjamin J. Stapley, Andrew J. Doig	48
18	Distinguishing Enzyme Structures from Non-enzymes Without Alignments 2003 ·Journal of Molecular Biology ·Paul D. Dobson, Andrew J. Doig	335
19	Urinary incontinence. Social aspects. 1973 ·PubMed ·Paul D. Dobson	1
20	MANAGEMENT OF INCONTINENCE IN THE HOME 1972 ·PubMed Central ·Paul D. Dobson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact